Provided by Tiger Fintech (Singapore) Pte. Ltd.

Verastem

5.67
-0.2100-3.57%
Volume:991.06K
Turnover:5.63M
Market Cap:311.56M
PE:-1.62
High:5.84
Open:5.78
Low:5.58
Close:5.88
Loading ...

Verastem (VSTM) Gets a Buy from Mizuho Securities

TIPRANKS
·
06 Jun

Verastem Announces Strategic Plans in Investor Webcast

TIPRANKS
·
03 Jun

Verastem announces updated data from GenFleet’s Phase 1 GFH375 study

TIPRANKS
·
02 Jun

Verastem Inc. Announces Positive Phase 1/2 Trial Results for GFH375, Showcasing Promising Efficacy in Pancreatic and Lung Cancers

Reuters
·
02 Jun

Verastem Oncology Announces Updated Data From Partner Genfleet Therapeutics’ Phase 1 Study in China of Gfh375 (VS-7375), an Oral Kras G12d (on/off) Inhibitor

THOMSON REUTERS
·
02 Jun

Verastem Oncology to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Reuters
·
28 May

Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA)

TIPRANKS
·
24 May

Verastem Says Pancreatic Cancer Patients in Phase 1/2 Trial of Avmapki Achieve 83% Overall Response Rate

MT Newswires Live
·
23 May

Verastem announces positive Phase 1/2 safety and efficacy results in PDAC

TIPRANKS
·
23 May

Verastem Inc Shares up11.8% at $8.36 After the Bell Following Avutometinib Plus Defactinib Drug Study Update

THOMSON REUTERS
·
23 May

Verastem Inc - Plans for Registrational Phase 3 Study Underway in Frontline Metastatic Pdac

THOMSON REUTERS
·
23 May

Verastem Oncology Announces Positive Updated Results From Ramp 205 Evaluating Avutometinib Plus Defactinib in Combination With Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

THOMSON REUTERS
·
23 May

Dan Paterson, President and CEO of Verastem Inc., Reports Disposal of Common Shares

Reuters
·
21 May

Tempus AI, Verastem to Develop Diagnostic Test for Ovarian Cancer Combination Treatment

MT Newswires Live
·
20 May

BRIEF-Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

Reuters
·
20 May

Tempus AI : Partners With Verastem to Develop Cdx for FDA-Approved Kras-Mutant Recurrent Low-Grade Ovarian Cancer Combination Treatment

THOMSON REUTERS
·
20 May

Alliance Global Partners Sticks to Its Buy Rating for Verastem (VSTM)

TIPRANKS
·
15 May

Verastem’s Strategic Focus and FDA Approval Drive Buy Rating

TIPRANKS
·
14 May

BRIEF-Verastem Q1 Basic EPS USD -0.96

Reuters
·
14 May

Verastem Q1 Adj. EPS $(0.79) Misses $(0.71) Estimate

Benzinga
·
14 May